Clinical Trials

84 enrolled

Solid Tumor Malignancies

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

366 enrolled

Advanced Solid Tumors

NCT07204340 2026-02-27

TLN-372 in Advanced KRAS Mutant Solid Tumors

240 enrolled

KRAS Mutant Solid Tumors

NCT04219254 2026-02-25

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

197 enrolled

Solid Tumor, Adult

NCT05067283 2026-02-12

KANDLELIT-001

830 enrolled

Advanced Solid Tumors

NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

98 enrolled

Advanced Solid Tumours

NCT06480552 2026-02-05

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

240 enrolled

Advanced Solid Tumors

NCT07182591 2026-02-03

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT07215637 2026-02-02

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

60 enrolled

Advanced Solid Tumors

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Advanced Solid Tumor

NCT07231458 2026-01-16

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

27 enrolled

Advanced Solid Tumors

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

186 enrolled

Advanced/Metastatic Solid Tumors

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

292 enrolled

Advanced or Metastatic Solid Tumors

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

192 enrolled

Solid Tumor Malignancies

NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Other solid neoplasmThoracic

20 enrolled

Mesothelioma, Malignant

NCT05547321 2025-11-25

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

150 enrolled

Advanced Solid Tumor

NCT07095868 2025-11-21

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

94 enrolled

Selected Types of Solid Tumor

NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

110 enrolled

Advanced Solid Cancer

NCT05732831 2025-11-14

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT06576037 2025-10-15

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Solid Tumor

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

65 enrolled

Solid Tumors

NCT05761223 2025-08-17

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

151 enrolled

Advanced Solid Tumor

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

183 enrolled

Advanced Solid Tumor

NCT06719362 2025-07-10

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

110 enrolled

Advanced Solid Tumors

NCT05086692 2025-07-09

ABILITY-1

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

115 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

320 enrolled

Other solid neoplasmThoracic

Advanced or Metastatic Solid Tumors

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

25 enrolled

Mesothelioma, Malignant

NCT06470763 2025-03-07

EXPAND-1

240 enrolled

Advanced Solid Tumor

NCT06035744 2025-03-03

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

86 enrolled

Advanced Solid Tumor

NCT05438329 2025-02-27

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

1,123 enrolled

Advanced Solid Tumor

NCT06293651 2025-02-12

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

125 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT06462794 2024-09-19

First In Human Study of CX-801 in Advanced Solid Tumors

121 enrolled